{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:37:23Z","timestamp":1790048243857,"version":"4.0.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T00:00:00Z","timestamp":1444694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1038\/nrendo.2015.164","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T09:38:51Z","timestamp":1444729131000},"page":"672-680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Endocrinology research\u2014reflecting on the past decade and looking to the next"],"prefix":"10.1038","volume":"11","author":[{"given":"Kevan C.","family":"Herold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Majzoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merri","family":"Pendergrass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schlumberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,13]]},"reference":[{"key":"BFnrendo2015164_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1056\/NEJMoa1314474","volume":"371","author":"SJ Russell","year":"2014","unstructured":"Russell, S. J.  et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N. Engl. J. Med. 371, 313\u2013325 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2337\/dc15-0078","volume":"38","author":"KM Miller","year":"2015","unstructured":"Miller, K. M.  et al. Current state of type 1 diabetes treatment in the US: updated data from the T1D Exchange clinic registry. Diabetes Care 38, 971\u2013978 (2015).","journal-title":"Diabetes Care"},{"key":"BFnrendo2015164_CR3","doi-asserted-by":"crossref","unstructured":"The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977\u2013986 (1993).","DOI":"10.1056\/NEJM199309303291401"},{"key":"BFnrendo2015164_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.molmed.2012.01.001","volume":"18","author":"JE Tooley","year":"2012","unstructured":"Tooley, J. E., Waldron-Lynch, F. & Herold, K. C. New and future immunomodulatory therapy in type 1 diabetes. Trends Mol. Med. 18, 173\u2013181 (2012).","journal-title":"Trends Mol. Med."},{"key":"BFnrendo2015164_CR5","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/ng.2215","volume":"44","author":"C Talchai","year":"2012","unstructured":"Talchai, C., Xuan, S., Kitamura, T., DePinho, R. A. & Accili, D. Generation of functional insulin-producing cells in the gut by Foxo1 ablation. Nat. Genet. 44, 406\u2013412 (2012).","journal-title":"Nat. Genet."},{"key":"BFnrendo2015164_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.cell.2014.09.040","volume":"159","author":"FW Pagliuca","year":"2014","unstructured":"Pagliuca, F. W.  et al. Generation of functional human pancreatic \u03b2 cells in vitro. Cell 159, 428\u2013439 (2014).","journal-title":"Cell"},{"key":"BFnrendo2015164_CR7","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa032922","volume":"350","author":"AL Gloyn","year":"2004","unstructured":"Gloyn, A. L.  et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 350, 1838\u20131849 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1056\/NEJMoa055068","volume":"355","author":"AP Babenko","year":"2006","unstructured":"Babenko, A. P.  et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med. 355, 456\u2013466 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa052521","volume":"354","author":"G Van den Berghe","year":"2006","unstructured":"Van den Berghe, G.  et al. Intensive insulin therapy in the medical ICU. N. Engl. J. Med. 354, 449\u2013461 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1056\/NEJMoa1314474","volume":"371","author":"SJ Russell","year":"2014","unstructured":"Russell, S. J.  et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N. Engl. J. Med. 371, 313\u2013325 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.cell.2014.09.040","volume":"159","author":"FW Pagliuca","year":"2014","unstructured":"Pagliuca, F. W.  et al. Generation of functional human pancreatic \u03b2 cells in vitro. Cell 159, 428\u2013439 (2014).","journal-title":"Cell"},{"key":"BFnrendo2015164_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa0810780","volume":"360","author":"AM Cypess","year":"2009","unstructured":"Cypess, A. M.  et al. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 360, 1509\u20131517 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.cell.2012.05.016","volume":"150","author":"J Wu","year":"2012","unstructured":"Wu, J.  et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 150, 366\u2013376 (2012).","journal-title":"Cell"},{"key":"BFnrendo2015164_CR14","doi-asserted-by":"publisher","first-page":"1241214","DOI":"10.1126\/science.1241214","volume":"341","author":"VK Ridaura","year":"2013","unstructured":"Ridaura, V. K.  et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214 (2013).","journal-title":"Science"},{"key":"BFnrendo2015164_CR15","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1056\/NEJMoa035322","volume":"349","author":"SB Seminara","year":"2003","unstructured":"Seminara, S. B.  et al. The GPR54 gene as a regulator of puberty. N. Engl. J. Med. 349, 1614\u20131627 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa073443","volume":"358","author":"MG Teles","year":"2008","unstructured":"Teles, M. G.  et al. A GPR54-activating mutation in a patient with central precocious puberty. N. Engl. J. Med. 358, 709\u2013715 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1056\/NEJMoa066494","volume":"357","author":"T Raivio","year":"2007","unstructured":"Raivio, T.  et al. Reversal of idiopathic hypogonadotropic hypogonadism. N. Engl. J. Med. 357, 863\u2013873 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/ng.382","volume":"41","author":"KK Ong","year":"2009","unstructured":"Ong, K. K.  et al. Genetic variation in LIN28B is associated with the timing of puberty. Nat. Genet. 41, 729\u201333 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrendo2015164_CR19","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1056\/NEJMoa1302160","volume":"368","author":"AP Abreu","year":"2013","unstructured":"Abreu, A. P.  et al. Central precocious puberty caused by mutations in the imprinted gene MKRN3. N. Engl. J. Med. 368, 2467\u20132475 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng1501","volume":"37","author":"LA Metherell","year":"2005","unstructured":"Metherell, L. A.  et al. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat. Genet. 37, 166\u2013170 (2005).","journal-title":"Nat. Genet."},{"key":"BFnrendo2015164_CR21","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1056\/NEJMoa1304603","volume":"369","author":"G Assie","year":"2013","unstructured":"Assie, G.  et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N. Engl. J. Med. 369, 2105\u20132114 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1310359","volume":"370","author":"F Beuschlein","year":"2014","unstructured":"Beuschlein, F.  et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. N. Engl. J. Med. 370, 1019\u20131028 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR23","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1210\/jc.2009-2546","volume":"95","author":"SA Rivkees","year":"2010","unstructured":"Rivkees, S. A. & Szarfman, A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J. Clin. Endocrinol. Metab. 95, 3260\u20133267 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2015164_CR24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings, S. R.  et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756\u2013765 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR25","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung, M. R.  et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412\u2013420 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature10637","volume":"480","author":"H Suga","year":"2011","unstructured":"Suga, H.  et al. Self-formation of functional adenohypophysis in three-dimensional culture. Nature 480, 57\u201362 (2011).","journal-title":"Nature"},{"key":"BFnrendo2015164_CR27","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.1073\/pnas.0801644105","volume":"105","author":"AS Gleiberman","year":"2008","unstructured":"Gleiberman, A. S.  et al. Genetic approaches identify adult pituitary stem cells. Proc. Natl Acad. Sci. USA 105, 6332\u20136337 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2015164_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.stem.2013.07.006","volume":"13","author":"K Rizzoti","year":"2013","unstructured":"Rizzoti, K., Akiyama, H. & Lovell-Badge, R. Mobilized adult pituitary stem cells contribute to endocrine regeneration in response to physiological demand. Cell Stem Cell 13, 419\u2013432 (2013).","journal-title":"Cell Stem Cell"},{"key":"BFnrendo2015164_CR29","doi-asserted-by":"publisher","first-page":"12515","DOI":"10.1073\/pnas.1105929108","volume":"108","author":"L Budry","year":"2011","unstructured":"Budry, L.  et al. Related pituitary cell lineages develop into interdigitated 3D cell networks. Proc. Natl Acad. Sci. USA 108, 12515\u201312520 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2015164_CR30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1947601910370979","volume":"1","author":"T Hosoyama","year":"2010","unstructured":"Hosoyama, T.  et al. A postnatal Pax7 progenitor gives rise to pituitary adenomas. Genes Cancer 1, 388\u2013402 (2010).","journal-title":"Genes Cancer"},{"key":"BFnrendo2015164_CR31","doi-asserted-by":"publisher","first-page":"17498","DOI":"10.1073\/pnas.0804810105","volume":"105","author":"V Chesnokova","year":"2008","unstructured":"Chesnokova, V.  et al. p21(Cip1) restrains pituitary tumor growth. Proc. Natl Acad. Sci. USA 105, 17498\u201317503 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2015164_CR32","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1172\/JCI60417","volume":"121","author":"H Fukuoka","year":"2011","unstructured":"Fukuoka, H.  et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J. Clin. Invest. 121, 4712\u20134721 (2011).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo2015164_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ng.3166","volume":"47","author":"M Reincke","year":"2015","unstructured":"Reincke, M.  et al. Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nat. Genet. 47, 31\u201338 (2015).","journal-title":"Nat. Genet."},{"key":"BFnrendo2015164_CR34","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1126\/science.1126100","volume":"312","author":"O Vierimaa","year":"2006","unstructured":"Vierimaa, O.  et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312, 1228\u20131230 (2006).","journal-title":"Science"},{"key":"BFnrendo2015164_CR35","first-page":"1265","volume":"372","author":"AF Daly","year":"2015","unstructured":"Daly, A. F., Trivellin, G. & Stratakis, C. A. Gigantism, acromegaly, and GPR101 mutations. N. Engl. J. Med. 372, 1265 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR36","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao, A.  et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N. Engl. J. Med. 366, 914\u2013924 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR37","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1210\/jc.2014-2032","volume":"99","author":"SJ Neggers","year":"2014","unstructured":"Neggers, S. J.  et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 99, 3644\u20133652 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2015164_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1210\/jc.2014-2468","volume":"100","author":"D Cuevas-Ramos","year":"2015","unstructured":"Cuevas-Ramos, D.  et al. A structural and functional acromegaly classification. J. Clin. Endocrinol. Metab. 100, 122\u2013131 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2015164_CR39","unstructured":"International Diabetes Federation. IDF Diabetes Atlas Sixth Edition \n                    [online]\n                    \n                  , (2014)."},{"key":"BFnrendo2015164_CR40","doi-asserted-by":"crossref","unstructured":"Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977\u2013986 (1993).","DOI":"10.1056\/NEJM199309303291401"},{"key":"BFnrendo2015164_CR41","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837\u2013853 (1998).","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"BFnrendo2015164_CR42","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein, H. C.  et al. Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545\u20132559 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR43","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00125-010-1864-z","volume":"53","author":"JS Yudkin","year":"2010","unstructured":"Yudkin, J. S., Richter, B. & Gale, E. A. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 53, 2079\u20132085 (2010).","journal-title":"Diabetologia"},{"key":"BFnrendo2015164_CR44","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2337\/dc13-0512","volume":"36","author":"I Raz","year":"2013","unstructured":"Raz, I.  et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 36, 1779\u20131788 (2013).","journal-title":"Diabetes Care"},{"key":"BFnrendo2015164_CR45","unstructured":"Haugen, B. R.  et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid (in press)."},{"key":"BFnrendo2015164_CR46","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676\u2013690 (2014)."},{"key":"BFnrendo2015164_CR47","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nrendo.2014.236","volume":"11","author":"JC Reed","year":"2015","unstructured":"Reed, J. C. & Herold, K. C. Thinking bedside at the bench: the NOD mouse model of T1DM. Nat. Rev. Endocrinol. 11, 308\u2013314 (2015).","journal-title":"Nat. Rev. Endocrinol."},{"key":"BFnrendo2015164_CR48","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1001\/jamainternmed.2013.4190","volume":"173","author":"L Bero","year":"2013","unstructured":"Bero, L. Industry sponsorship and research outcome. A Cochrane Review. JAMA Intern. Med. 173, 580\u2013581 (2013).","journal-title":"JAMA Intern. Med."},{"key":"BFnrendo2015164_CR49","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrendo.2012.257","volume":"9","author":"Y Ito","year":"2013","unstructured":"Ito, Y., Nikiforov, Y., Schlumberger, M. & Vigneri, R. Increasing incidence of thyroid cancer: controversies explored. Nat. Rev. Endocrinol. 9, 178\u2013184 (2013).","journal-title":"Nat. Rev. Endocrinol."},{"key":"BFnrendo2015164_CR50","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1210\/jc.2010-2708","volume":"96","author":"M Brassard","year":"2011","unstructured":"Brassard, M.  et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J. Clin. Endocrinol. Metab. 96, 1352\u20131359 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2015164_CR51","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","volume":"381","author":"MM Xing","year":"2013","unstructured":"Xing, M. M., Haugen, B. & Schlumberger, M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 381, 1058\u20131069 (2013).","journal-title":"Lancet"},{"key":"BFnrendo2015164_CR52","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante, C.  et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892\u20132899 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2015164_CR53","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","volume":"2","author":"M Schlumberger","year":"2014","unstructured":"Schlumberger, M.  et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer: recommendations by an international expert panel. Lancet Diabetes Endocrinol. 2, 356\u2013358 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"BFnrendo2015164_CR54","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose, M. S.  et al. A randomized trial of sorafenib for 131I-refractory differentiated thyroid cancer. Lancet 384, 319\u2013328 (2014).","journal-title":"Lancet"},{"key":"BFnrendo2015164_CR55","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger, M.  et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621\u2013630 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR56","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nri3422","volume":"13","author":"K Herold","year":"2013","unstructured":"Herold, K., Vignali, D. A., Cooke, A. & Bluestone, J. Type 1 diabetes: Translating mechanistic observations into effective clinical outcomes. Nat. Rev. Immunol. 13, 243\u2013256 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrendo2015164_CR57","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha, M. R.  et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2, 875\u2013884 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"BFnrendo2015164_CR58","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes Care 36, 1033\u20131046 (2013).","DOI":"10.2337\/dc12-2625"},{"key":"BFnrendo2015164_CR59","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMsa1213829","volume":"368","author":"MK Ali","year":"2013","unstructured":"Ali, M. K.  et al. Achievement of goals in U. S. diabetes care, 1999\u20132010. N. Engl. J. Med. 368, 1613\u20131624 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR60","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1056\/NEJMoa1109589","volume":"366","author":"U Mallick","year":"2012","unstructured":"Mallick, U.  et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 366, 1674\u20131685 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR61","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1108586","volume":"366","author":"M Schlumberger","year":"2012","unstructured":"Schlumberger, M.  et al. Strategies of radioiodine ablation in low-risk thyroid cancer patients. N. Engl. J. Med. 366, 1663\u20131673 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR62","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"Ho, A. L.  et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N. Engl. J. Med. 368, 623\u2013632 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2015164_CR63","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1084\/jem.20111502","volume":"208","author":"JF Mohan","year":"2011","unstructured":"Mohan, J. F., Petzold, S. J. & Unanue, E. R. Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J. Exp. Med. 208, 2375\u20132383 (2011).","journal-title":"J. Exp. Med."},{"key":"BFnrendo2015164_CR64","doi-asserted-by":"publisher","first-page":"10978","DOI":"10.1073\/pnas.1006545107","volume":"107","author":"BD Stadinski","year":"2010","unstructured":"Stadinski, B. D.  et al. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc. Natl Acad. Sci. USA 107, 10978\u201310983 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2015164_CR65","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1172\/JCI78142","volume":"125","author":"KC Herold","year":"2015","unstructured":"Herold, K. C.  et al. \u03b2 cell death and dysfunction during type 1 diabetes development in at-risk individuals. J. Clin. Invest. 125, 1163\u20131173 (2015).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo2015164_CR66","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/dmrr.1243","volume":"27","author":"R Mallone","year":"2011","unstructured":"Mallone, R.  et al. Immunology of Diabetes Society T-Cell Workshop: HLA class I tetramer-directed epitope validation initiative T-Cell Workshop Report-HLA Class I Tetramer Validation Initiative. Diabetes Metab. Res. Rev. 27, 720\u2013726 (2011).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"BFnrendo2015164_CR67","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1172\/JCI78448","volume":"125","author":"A Cariboni","year":"2015","unstructured":"Cariboni A.  et al. Dysfunctional SEMA3E signaling underlies gonadotropin-releasing hormone neuron deficiency in Kallmann syndrome. J. Clin. Invest. 125, 2413\u20132428 (2015).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2015.164","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2015.164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2015.164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:45:36Z","timestamp":1684467936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2015.164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,13]]},"references-count":67,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["BFnrendo2015164"],"URL":"https:\/\/doi.org\/10.1038\/nrendo.2015.164","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,13]]},"assertion":[{"value":"13 October 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.A.M. is named as an inventor on two patent applications related to obesity. S.M. has been a scientific consultant for Chiasma and Isis; has received research grant support from Ipsen and Pfizer; and has been an education consultant for Novartis. M.S. has received research support and honoraria and has been on advisory boards for AstraZeneca, Bayer, Eisai and Exelixis-Sobi. K.C.H. and M.P. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}